Profusa, Inc. (NASDAQ:PFSA – Get Free Report) major shareholder Financial Lp Hrt sold 42,411 shares of the stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $0.89, for a total transaction of $37,745.79. Following the completion of the sale, the insider owned 74,198 shares of the company’s stock, valued at approximately $66,036.22. The trade was a 36.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Financial Lp Hrt also recently made the following trade(s):
- On Wednesday, August 12th, Financial Lp Hrt purchased 5,585 shares of Profusa stock. The shares were purchased at an average price of $0.96 per share, for a total transaction of $5,361.60.
- On Tuesday, August 4th, Financial Lp Hrt purchased 1,368 shares of Profusa stock. The stock was purchased at an average cost of $0.95 per share, with a total value of $1,299.60.
- On Monday, August 3rd, Financial Lp Hrt acquired 14,556 shares of Profusa stock. The stock was purchased at an average price of $0.96 per share, with a total value of $13,973.76.
- On Wednesday, July 29th, Financial Lp Hrt acquired 1,310 shares of Profusa stock. The shares were purchased at an average cost of $1.01 per share, for a total transaction of $1,323.10.
Profusa Stock Performance
Shares of NASDAQ:PFSA traded down $0.06 during trading on Friday, hitting $0.90. 46,269 shares of the stock were exchanged, compared to its average volume of 223,125. The company has a market capitalization of $170,050.00, a price-to-earnings ratio of -0.00 and a beta of 0.52. Profusa, Inc. has a 1-year low of $0.81 and a 1-year high of $1,297.50. The company’s fifty day simple moving average is $2.85 and its 200-day simple moving average is $25.06.
Wall Street Analyst Weigh In
PFSA has been the topic of several analyst reports. Wall Street Zen upgraded Profusa from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Profusa in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.
Check Out Our Latest Stock Report on PFSA
Profusa Company Profile
Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.
The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.
Featured Articles
- Five stocks we like better than Profusa
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Profusa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profusa and related companies with MarketBeat.com's FREE daily email newsletter.
